Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice
Mutations in the Leucine Rich Repeat Kinase 2 (LRRK2) gene, first described in 2004 have now emerged as the most important genetic finding in both autosomal dominant and sporadic Parkinson's disease (PD). While a formidable research effort has ensued since the initial gene discovery, little is...
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2010-12-01
|
Series: | Neurobiology of Disease |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0969996110002342 |
id |
doaj-826034551a614ddaa028378afe1807f9 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
H.L. Melrose J.C. Dächsel B. Behrouz S.J. Lincoln M. Yue K.M. Hinkle C.B. Kent E. Korvatska J.P. Taylor L. Witten Y.-Q. Liang J.E. Beevers M. Boules B.N. Dugger V.A. Serna A. Gaukhman X. Yu M. Castanedes-Casey A.T. Braithwaite S. Ogholikhan N. Yu D. Bass G. Tyndall G.D. Schellenberg D.W. Dickson C. Janus M.J. Farrer |
spellingShingle |
H.L. Melrose J.C. Dächsel B. Behrouz S.J. Lincoln M. Yue K.M. Hinkle C.B. Kent E. Korvatska J.P. Taylor L. Witten Y.-Q. Liang J.E. Beevers M. Boules B.N. Dugger V.A. Serna A. Gaukhman X. Yu M. Castanedes-Casey A.T. Braithwaite S. Ogholikhan N. Yu D. Bass G. Tyndall G.D. Schellenberg D.W. Dickson C. Janus M.J. Farrer Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice Neurobiology of Disease Parkinson's disease Transgenic Dopamine Microdialysis Neuropathology Anxiety |
author_facet |
H.L. Melrose J.C. Dächsel B. Behrouz S.J. Lincoln M. Yue K.M. Hinkle C.B. Kent E. Korvatska J.P. Taylor L. Witten Y.-Q. Liang J.E. Beevers M. Boules B.N. Dugger V.A. Serna A. Gaukhman X. Yu M. Castanedes-Casey A.T. Braithwaite S. Ogholikhan N. Yu D. Bass G. Tyndall G.D. Schellenberg D.W. Dickson C. Janus M.J. Farrer |
author_sort |
H.L. Melrose |
title |
Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice |
title_short |
Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice |
title_full |
Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice |
title_fullStr |
Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice |
title_full_unstemmed |
Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice |
title_sort |
impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human lrrk2 transgenic mice |
publisher |
Elsevier |
series |
Neurobiology of Disease |
issn |
1095-953X |
publishDate |
2010-12-01 |
description |
Mutations in the Leucine Rich Repeat Kinase 2 (LRRK2) gene, first described in 2004 have now emerged as the most important genetic finding in both autosomal dominant and sporadic Parkinson's disease (PD). While a formidable research effort has ensued since the initial gene discovery, little is known of either the normal or the pathological role of LRRK2. We have created lines of mice that express human wild-type (hWT) or G2019S Lrrk2 via bacterial artificial chromosome (BAC) transgenesis. In vivo analysis of the dopaminergic system revealed abnormal dopamine neurotransmission in both hWT and G2019S transgenic mice evidenced by a decrease in extra-cellular dopamine levels, which was detected without pharmacological manipulation. Immunopathological analysis revealed changes in localization and increased phosphorylation of microtubule binding protein tau in G2019S mice. Quantitative biochemical analysis confirmed the presence of differential phospho-tau species in G2019S mice but surprisingly, upon dephosphorylation the tau isoform banding pattern in G2019S mice remained altered. This suggests that other post-translational modifications of tau occur in G2019S mice. We hypothesize that Lrrk2 may impact on tau processing which subsequently leads to increased phosphorylation. Our models will be useful for further understanding of the mechanistic actions of LRRK2 and future therapeutic screening. |
topic |
Parkinson's disease Transgenic Dopamine Microdialysis Neuropathology Anxiety |
url |
http://www.sciencedirect.com/science/article/pii/S0969996110002342 |
work_keys_str_mv |
AT hlmelrose impaireddopaminergicneurotransmissionandmicrotubuleassociatedproteintaualterationsinhumanlrrk2transgenicmice AT jcdachsel impaireddopaminergicneurotransmissionandmicrotubuleassociatedproteintaualterationsinhumanlrrk2transgenicmice AT bbehrouz impaireddopaminergicneurotransmissionandmicrotubuleassociatedproteintaualterationsinhumanlrrk2transgenicmice AT sjlincoln impaireddopaminergicneurotransmissionandmicrotubuleassociatedproteintaualterationsinhumanlrrk2transgenicmice AT myue impaireddopaminergicneurotransmissionandmicrotubuleassociatedproteintaualterationsinhumanlrrk2transgenicmice AT kmhinkle impaireddopaminergicneurotransmissionandmicrotubuleassociatedproteintaualterationsinhumanlrrk2transgenicmice AT cbkent impaireddopaminergicneurotransmissionandmicrotubuleassociatedproteintaualterationsinhumanlrrk2transgenicmice AT ekorvatska impaireddopaminergicneurotransmissionandmicrotubuleassociatedproteintaualterationsinhumanlrrk2transgenicmice AT jptaylor impaireddopaminergicneurotransmissionandmicrotubuleassociatedproteintaualterationsinhumanlrrk2transgenicmice AT lwitten impaireddopaminergicneurotransmissionandmicrotubuleassociatedproteintaualterationsinhumanlrrk2transgenicmice AT yqliang impaireddopaminergicneurotransmissionandmicrotubuleassociatedproteintaualterationsinhumanlrrk2transgenicmice AT jebeevers impaireddopaminergicneurotransmissionandmicrotubuleassociatedproteintaualterationsinhumanlrrk2transgenicmice AT mboules impaireddopaminergicneurotransmissionandmicrotubuleassociatedproteintaualterationsinhumanlrrk2transgenicmice AT bndugger impaireddopaminergicneurotransmissionandmicrotubuleassociatedproteintaualterationsinhumanlrrk2transgenicmice AT vaserna impaireddopaminergicneurotransmissionandmicrotubuleassociatedproteintaualterationsinhumanlrrk2transgenicmice AT agaukhman impaireddopaminergicneurotransmissionandmicrotubuleassociatedproteintaualterationsinhumanlrrk2transgenicmice AT xyu impaireddopaminergicneurotransmissionandmicrotubuleassociatedproteintaualterationsinhumanlrrk2transgenicmice AT mcastanedescasey impaireddopaminergicneurotransmissionandmicrotubuleassociatedproteintaualterationsinhumanlrrk2transgenicmice AT atbraithwaite impaireddopaminergicneurotransmissionandmicrotubuleassociatedproteintaualterationsinhumanlrrk2transgenicmice AT sogholikhan impaireddopaminergicneurotransmissionandmicrotubuleassociatedproteintaualterationsinhumanlrrk2transgenicmice AT nyu impaireddopaminergicneurotransmissionandmicrotubuleassociatedproteintaualterationsinhumanlrrk2transgenicmice AT dbass impaireddopaminergicneurotransmissionandmicrotubuleassociatedproteintaualterationsinhumanlrrk2transgenicmice AT gtyndall impaireddopaminergicneurotransmissionandmicrotubuleassociatedproteintaualterationsinhumanlrrk2transgenicmice AT gdschellenberg impaireddopaminergicneurotransmissionandmicrotubuleassociatedproteintaualterationsinhumanlrrk2transgenicmice AT dwdickson impaireddopaminergicneurotransmissionandmicrotubuleassociatedproteintaualterationsinhumanlrrk2transgenicmice AT cjanus impaireddopaminergicneurotransmissionandmicrotubuleassociatedproteintaualterationsinhumanlrrk2transgenicmice AT mjfarrer impaireddopaminergicneurotransmissionandmicrotubuleassociatedproteintaualterationsinhumanlrrk2transgenicmice |
_version_ |
1724208706539749376 |
spelling |
doaj-826034551a614ddaa028378afe1807f92021-03-22T12:35:43ZengElsevierNeurobiology of Disease1095-953X2010-12-01403503517Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic miceH.L. Melrose0J.C. Dächsel1B. Behrouz2S.J. Lincoln3M. Yue4K.M. Hinkle5C.B. Kent6E. Korvatska7J.P. Taylor8L. Witten9Y.-Q. Liang10J.E. Beevers11M. Boules12B.N. Dugger13V.A. Serna14A. Gaukhman15X. Yu16M. Castanedes-Casey17A.T. Braithwaite18S. Ogholikhan19N. Yu20D. Bass21G. Tyndall22G.D. Schellenberg23D.W. Dickson24C. Janus25M.J. Farrer26Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA; Corresponding authors. Laboratories of Neurogenetics, Mayo Clinic, Department of Neuroscience, 4500 San Pablo Road, Jacksonville, FL 32224, USA. Fax: +1 904 953 7370.Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USADepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USADepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USADepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USADepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USADepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USAVeteran Affairs Medical Center, University of Washington, 1660 S. Columbian Way, Seattle, WA 98108, USADepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USAH. Lundbeck A/S, Ottiliavej 9, Copenhagen, DK-2500, DenmarkDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USADepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USADepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USADepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USADepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USADepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USADepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USADepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USADepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USADepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USADepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USADepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USADepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USAPathology and Laboratory Medicine, University of Pennsylvania School of Medicine, 422 Curie Boulevard, Philadelphia, PA 19104, USADepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USADepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USADepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA; Corresponding authors. Laboratories of Neurogenetics, Mayo Clinic, Department of Neuroscience, 4500 San Pablo Road, Jacksonville, FL 32224, USA. Fax: +1 904 953 7370.Mutations in the Leucine Rich Repeat Kinase 2 (LRRK2) gene, first described in 2004 have now emerged as the most important genetic finding in both autosomal dominant and sporadic Parkinson's disease (PD). While a formidable research effort has ensued since the initial gene discovery, little is known of either the normal or the pathological role of LRRK2. We have created lines of mice that express human wild-type (hWT) or G2019S Lrrk2 via bacterial artificial chromosome (BAC) transgenesis. In vivo analysis of the dopaminergic system revealed abnormal dopamine neurotransmission in both hWT and G2019S transgenic mice evidenced by a decrease in extra-cellular dopamine levels, which was detected without pharmacological manipulation. Immunopathological analysis revealed changes in localization and increased phosphorylation of microtubule binding protein tau in G2019S mice. Quantitative biochemical analysis confirmed the presence of differential phospho-tau species in G2019S mice but surprisingly, upon dephosphorylation the tau isoform banding pattern in G2019S mice remained altered. This suggests that other post-translational modifications of tau occur in G2019S mice. We hypothesize that Lrrk2 may impact on tau processing which subsequently leads to increased phosphorylation. Our models will be useful for further understanding of the mechanistic actions of LRRK2 and future therapeutic screening.http://www.sciencedirect.com/science/article/pii/S0969996110002342Parkinson's diseaseTransgenicDopamineMicrodialysisNeuropathologyAnxiety |